AMA, AHA Call For Drug Pricing Transparency, Increased Competition
Published by Inside Health Policy
Representatives from the American Medical Association and the American Hospital Association called for increased drug pricing transparency and reduced regulations to increase competition at a panel on Monday (Sept. 25) on the cost of drugs at America’s Health Insurance Plans’ Medicare conference.
AMA Senior Vice President for Advocacy Richard Deem said that not much will change when it comes to rising costs until the industry achieves transparency in drug pricing.
“Physicians should be subject to transparency in terms to prices in health care, as should hospitals, as should PBMs as should pharmaceutical companies. Because right now it’s really hard. You can’t make good policy unless you have good data,” Deem said.
AHA Senior Vice President for Public Policy Ashley Thompson added that in order for there to be more transparency in drug pricing, more disclosure requirements should be tied to drug pricing and research and development when companies apply for drug approval.
Thompson also called for more competition and innovation. She said that AHA supports fast-tracking generic applications when no generic competition exists, incentivizing generic manufacturers with fast-track rewards, deeming pay-for-delay tactics to be presumptively illegal and increasing oversight of such agreements, and limiting the orphan drug incentive to true orphan drugs.
Deem expressed concern about laws and regulations used to stifle competition, such as use of the patent process or risk evaluation and mitigation strategies. AMA has called for an end to patent evergreening and recommended policy requiring a modest change in the product in order to extend the patent. He also said that the AMA wants FDA to minimize barriers for new products.
“We’ve got to continue to work together in this process. Health costs are a problem for the entire sector,” Deem said. “I think that those of us, whether it’s health plans, hospitals, physicians, drug-device manufacturers, we need to step up to the plate and own our part in the cost increase.” — Ariel Cohen
Click here to see the original article on the Inside Health Policy website.
Recent Posts
-
Pharmacy Community Stands Together to Protect Seniors and Prevent a Long-Term Care Crisis
The Senior Care Pharmacy Coalition (SCPC), representing the nation’s long-term care pharmacies, the American Society of Consultant Pharmacists (ASCP), representing pharmacists and pharmacies dedicated to managing medications for older adults and medically complex patients, and the National Community Pharmacists Association (NCPA), representing community pharmacists nationwide, stand united in support of immediate action—whether through legislation or […]
-
Rep. Beth Van Duyne: Congress can save seniors’ access to medications before it’s too late
Seniors in nursing homes across the country depend on round-the-clock care and medications, perhaps more than any other American patient population. In turn, the nursing homes and assisted living facilities that care for them depend on a small number of specialized long-term care (LTC) pharmacies to ensure their patients have access to the prescription meds they need.
-
Bill Aims to Offset Reimbursement Losses for Long-Term Care Pharmacies Catering to Nursing Homes
Starting in January, falling prices for costly drugs may strain long-term care pharmacies, but proposed legislation backed by advocacy groups aims to subsidize some of this loss. And nursing home advocacy groups are among those urging Congress to pass the Preserving Patient Access to Long-Term Care Pharmacies Act.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.